Sage Therapeutics (NASDAQ:SAGE) : Traders are bullish on Sage Therapeutics (NASDAQ:SAGE) as it has outperformed the S&P 500 by a wide margin of 10.01% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 7.85%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 9.23% in the last 1 week, and is up 11.78% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -53.63% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $77.48 and the one year low was seen on Mar 23, 2016. The 50-Day Moving Average price is $30.99 and the 200 Day Moving Average price is recorded at $35.44.
The stock has recorded a 20-day Moving Average of 14.49% and the 50-Day Moving Average is 5.98%.
Sage Therapeutics (NASDAQ:SAGE): stock turned positive on Friday. Though the stock opened at $32.21, the bulls momentum made the stock top out at $34.38 level for the day. The stock recorded a low of $31.9 and closed the trading day at $33.97, in the green by 5.63%. The total traded volume for the day was 765,803. The stock had closed at $32.16 in the previous days trading.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director 10% owner of Sage Therapeutics, Inc., Starr Kevin P had sold 850,000 shares worth of $26,562,500 in a transaction dated May 16, 2016. In this transaction, 850,000 shares were sold at $31.25 per share.
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Companys lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.